Trial Profile
CHemotherapy Plus Enzalutamide In First Line Therapy for Castration Resistant prOstate caNcer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Docetaxel; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms Ch.E.I.R.O.N.; CHEIRON
- 03 Aug 2021 Results published in the European Journal of Cancer
- 15 Feb 2020 Preliminary results (n=120) assessing Enzalutamide activity in post-progression setting of CHEIRON enzalutamide + docetaxel arm, presented at the 2020 Genitourinary Cancers Symposium.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology